Vienna, Austria

ESTRO 2023

Session Item

CNS
6002
Poster (Digital)
Clinical
Radionecrosis in brain metastases, intact or cavities, treated with stereotactic radiotherapy
Sandra Fernandez Alonso, Spain
PO-1110

Abstract

Radionecrosis in brain metastases, intact or cavities, treated with stereotactic radiotherapy
Authors:

Sandra Fernandez Alonso1, Sandra Guardado González1, Gustavo Pozo Rodríguez2, Cristian Arias Guillén1, Claudia F. Pedrero1, Rafael D´Ambrosi1, José Fermín Pérez-Regadera Gomez1

1Hospital Universitario 12 de Octubre, Radiation Oncology, Madrid, Spain; 2Hospital Universitario 12 de Octubre, Medical Physicist, Madrid, Spain

Show Affiliations
Purpose or Objective

To determine the incidence of radionecrosis (RN) and the factors associated with its appearance in patients treated with single-session radiosurgery (SF-SRS) or fractionated stereotactic radiotherapy (MF-SRS).

Material and Methods

183 patients (57% women and 43% men) diagnosed with 1 to 5 brain metastases (232 lesions) treated between 2013 and 2020 were included and retrospectively analyzed.

An MRI was performed 3 months after RT and then every six months.

The association between variables was established with the Fisher or Chi-square test and survival with the Log-Rank test.



Results

Mean age was 59 years and mean lesion was 18mm (9-25mm).

Primary tumor histology: NSCLC 51%, breast 25%, melanoma 8%, kidney 5%, colorectal 4%, other 7%.

RPA classification: I 48% and II 52%.

49% had received previous local treatment; 67% WBRT, 23% surgery and 10% WBRT+surgery.

62% received SF-SRS. Dose administered: 15Gy 88%, 18Gy 10% and 2% other dose.

38% received MF-SRS. Dose administered: 35Gy (7x5Gy) 62%, 30Gy (6x5Gy) 25% and 13% other dose.

There were no significant differences between SF-SRS and MF-SRS in terms of age, lesion , sex, histology or RPA.

Regarding previous local treatment, surgery was more frequent in MF-SRS (13% vs 3%) and WBRT in SF-SRS (27% vs 7%) (p=0.01).

RN was observed in 19% of patients, with a median time of appearance of 6 months (3.5-16) post-treatment.

85% of RN occurred in the SF-SRS group and 15% in the MF-SRS group (p=0.01).

The mean PTV volume of the lesions that developed RN was 4cc, with a compliance index of 1.7, isocenter dose mean 17.6Gy and marginal dose mean 14.6Gy.

44% of RN occurred in lesions between 10-20mm, 32% in those greater than 20mm and 24% in those less than 10mm.

Using a ROC curve and the Youden`s index, the area under the lesion curve was 0.507 (0.402-0.612, p=0.05). The cut-off point was 15mm, with a sensitivity and specificity of developing RN of 68% and 46% respectively.


53% of RN were symptomatic; 83% of the RN in the MF-SRS group and 46% of the RN in the SF-SRS group.

Univariate analysis showed that receiving SF-SRS (OR 3.5, 1.4-9) or prior WBRT (OR 5.2, 1.1-24.1) were predictors of developing RN.

We found no relationship between histology or dose received and RN (p=0.8).

Patients with RN had higher V10 mean and V12 mean, but without significant differences: V10 10cc vs 8cc and V12 7cc vs 6cc.

After a median follow-up of 4 years, the median OS was 2.5 years (1-5) and the median RN free survival was 2.8 years (1.8-5.4).

The estimated RN free survival in the MF-SRS group at 1, 3 and 5 years was 94% (8-98), 91% (78-96) and 76% (34-93) and in the SF-SRS group was 78% (68-85), 64% (49-76) and 42% (20-63) respectively (p=0.02).





Conclusion

RN is related to lesion size, SF-SRS and previous WBRT.

The lesion diameter with the highest sensitivity and specificity to develop RN was 15mm.

Approximately, half of RN were symptomatic, related to having received MF-SRS.